We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

A malaria vaccine has become the first to provide 100 per cent protection against the disease, confounding critics and surpassing any other experimental malaria vaccine tested, Nature News reports today.

The vaccine, developed and tested in the United States, will now be tested further in clinical trials in Africa, starting at the Ifakara Health Institute in Tanzania. If those are successful, the vaccine may be licensed as early as four years from now.

The results, published today in Science, demonstrate for the first time the concept that a malaria vaccine can provide a high level of protection, raising cautious optimism amongst researchers.

So far the new vaccine has only been tested in the phase I safety trial, in a small study on 40 volunteers. Also, the vaccine was given intravenously, making it difficult to administer in mass vaccination campaigns or to give to children.

There is currently no effective vaccine for malaria, a disease that kills around 660,000 people a year, mostly children.

Link to full story in Nature News

Link to full study in Science


Science doi: 10.1126/science.1241800

Related topics